Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial
In allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk myeloid disorders, the intensity of the conditioning regimen correlates with the risk of relapse, but its benefit may be offset by its risk of toxicity.From 2017 to 2023, 31 patients with high-risk acute myeloid leukemia (AML, n=20) or myelodysplastic syndrome (MDS, n=5), or chronic myeloid leukemia (CML, n=3) in accelerated phase or blast crisis, were enrolled into a prospective phase II clinical trial of allogeneic HSCT using myeloablative TMI at 9Gy in combination with standard myeloablative fludarabine and targeted IV busulfan (FluBu4) chemother...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Lucas Maahs, Matthew Koshy, Karen Sweiss, Kang-hyun Ahn, Zhengjia Chen, Chukwuemeka Uzoka, Carlos Galvez, Paul Rubinstein, John Quigley, Santosh L Saraf, Ana Avila Rodriguez, Bulent Aydogan, Nadim Mahmud, Damiano Rondelli Tags: 209 Source Type: research
Limited Impact of Donor-Recipient Weight Difference on Outcomes of Allogeneic Hematopoietic Cell Transplantation
Donor-recipient weight difference may be an important consideration in selection of suitable donors in allogeneic hematopoietic cell transplantation (HCT), as it can affect stem cell yield during harvesting. However, the impact of donor-patient weight difference on transplant outcomes remains largely unknown. We retrospectively analyzed 841 consecutive patients transplanted at Princess Margaret Hospital 2018-2023. The majority of patients received HCT for acute myeloid leukaemia (48.3%) or myelodysplastic syndrome (16.9%) using matched unrelated (48.5%) or matched related (23.3%) donors. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Caden Chiarello, Mats Remberger, Carol Chen, Armin Gerbitz, Dennis (Dong Hwan) Kim, Rajat Kumar, Wilson Lam, Arjun D. Law, Jeff Lipton, Fotios V. Michelis, Igor Novitzky-Basso, Auro Viswabandya, Jonas Mattsson, Ivan Pasic Tags: 323 Source Type: research
Treatment of Post-Allogeneic HCT Relapsed AML/MDS with a Combination of Hypomethylating Agent, Venetoclax (HMA/VEN) and Donor Lymphocyte Infusion (DLI)
There is no standard of care for relapsed myeloid neoplasms (acute myeloid leukemia- AML/myelodysplastic syndrome-MDS) after allogeneic hematopoietic cell therapy (HCT). Intensive chemotherapy has been ineffective/toxic and DLI alone has had modest responses in this setting. When one compares DLI to second allogeneic HCT the responses are equivalent. More recently there is evidence in AML that HMA/VEN combination produces remission even in relapsed disease. In this retrospective analysis we reviewed patients with AML/MDS who relapsed post HCT and received (HMA+/-VEN) followed by DLI. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Stanislav A Ivanov, Yehuda E Deutsch, Jennifer Logue, Jose Sandoval Sus, Carlos Silva, Nina Nguyen, Claudia E Paba Prada, Fernando Vargas Madueno, Hugo F Fernandez Tags: 556 Source Type: research
Survival Outcomes after Relapse in Patients Who Underwent Haploidentical Stem Cell Transplantation (haplo-SCT)
Relapse remains the most common cause of relapse-related mortality following hematopoietic stem cell transplantation (HSCT) with limited treatment options and an overall poor prognosis. Therefore, it is important to understand the characteristics, survival outcome, predictive factors, and emerging treatment options for these high-risk patients. There is limited data in this regard for patients who underwent haplo-SCT. We aimed from this study to assess survival outcomes of patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS) who underwent haplo-SCT. (Source: Biol...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Supawee Saengboon, Stefan O. Ciurea, Uday R. Popat, Muzaffar H. Qazilbash, Jeremy Ramdial, Partow Kebriaei, Elizabeth J. Shpall, Richard E. Champlin, Samer A. Srour Tags: 557 Source Type: research
Access to Allogeneic Hematopoietic Cell Transplant for Patients with Hematologic Malignancies in Oregon
Hematologic malignancies are the main indication for allogeneic hematopoietic cell transplant (HCT) in adults. Despite advancements over time, access to HCT remains a challenge for certain groups based on non-biological factors. In this retrospective study, we identified sociodemographic factors influencing treatment with allogenic HCT for adult patients with acute leukemia and myelodysplastic syndrome at Oregon Health& Science University (OHSU). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Danielle Brouillard, Staci Williamson, LeeAnn Kamerman, Brittany O'Barr, Jessie Myers, Maryam Rezaie, Rachel Cook, Amrita Desai, Arpita P Gandhi, Brandon Hayes-Lattin, Jessica T. Leonard, Richard T. Maziarz, Gabrielle Meyers, Yazan Migdady, Laura F. Newel Tags: 588 Source Type: research
Clinical Challenges of Emerging Acquired Autoinflammatory Diseases, Including VEXAS Syndrome
Intern Med. 2024 Feb 1. doi: 10.2169/internalmedicine.3219-23. Online ahead of print.ABSTRACTVacuoles, E1-ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome, caused by an acquired mutation in the ubiquitin-activating enzyme ubiquitin-like modifier activating enzyme 1 (UBA1), was discovered in 2020. Since then, many cases have been reported worldwide. Recently, we performed UBA1 genetic testing in suspected cases of VEXAS throughout Japan and investigated the clinical features of these cases. Most cases were elderly patients in their 70s with clinical features consistent with VEXAS syndrome, s...
Source: Internal Medicine - January 31, 2024 Category: Internal Medicine Authors: Yohei Kirino Source Type: research
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
Leukemia, Published online: 31 January 2024; doi:10.1038/s41375-024-02161-6Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial (Source: Leukemia)
Source: Leukemia - January 31, 2024 Category: Hematology Authors: A. A. van de Loosdrecht E. M. P. Cremers C. Alhan C. Duetz F. E. M. in ’t Hout H. A. Visser-Wisselaar D. A. Chitu A. Verbrugge S. M. Cunha G. J. Ossenkoppele J. J. W. M. Janssen S. K. Klein E. Vellenga G. A. Huls P. Muus S. M. C. Langemeijer G. E. de Gr Source Type: research
Validation of a novel algorithm with a high specificity in ruling out MDS
CONCLUSION: The possibility of reliably excluding MDS from differential diagnosis based on peripheral blood lab work appears to be attractive for patients and physicians alike while the confirmation of MDS diagnosis still requires a bone marrow biopsy.PMID:38284270 | DOI:10.1111/ijlh.14234 (Source: International Journal of Laboratory Hematology)
Source: International Journal of Laboratory Hematology - January 29, 2024 Category: Hematology Authors: Felicitas Schulz Kathrin Nachtkamp Howard S Oster Moshe Mittelman Norbert Gattermann Sarah Schweier Carmen Barthuber Ulrich Germing Source Type: research
Spliceosomal helicases DDX41/SACY-1 and PRP22/MOG-5 both contribute to proofreading against proximal 3' splice site usage
RNA. 2024 Jan 24:rna.079888.123. doi: 10.1261/rna.079888.123. Online ahead of print.ABSTRACTRNA helicases drive necessary rearrangements and ensure fidelity during the pre-mRNA splicing cycle. DEAD-box helicase DDX41 has been linked to human disease and has recently been shown to interact with DEAH-box helicase PRP22 in the spliceosomal C* complex, yet its function in splicing remains unknown. Depletion of DDX41 homolog SACY-1 from somatic cells has been previously shown to lead to changes in alternative 3' splice site usage. Here, we show by transcriptomic analysis of published and novel datasets that SACY-1 perturbation ...
Source: RNA - January 29, 2024 Category: Genetics & Stem Cells Authors: Kenneth Osterhoudt Orazio R Bagno Sol Katzman Alan M Zahler Source Type: research
Meta-analysis of decitabine pretreatment-based allogeneic hematopoietic stem cell transplantation affecting transplantation-related complications and prognosis in patients with malignant hematological disease
Cell Mol Biol (Noisy-le-grand). 2023 Dec 20;69(14):69-75. doi: 10.14715/cmb/2023.69.14.11.ABSTRACTMalignant hematological diseases (MHD) are a kind of bone marrow hematopoietic system disease caused by malignant clonal proliferation, including leukemia, lymphoma, myelodysplastic syndrome, etc. At present, there are too few meta-analyses on the effect of decitabine pretreatment-based allogeneic hematopoietic stem cell transplantation (allo-HSCT) on transplantation-related complications and prognosis of MHD patients. A systematic search of PubMed, MEDLINE, Science Direct, The Cochrane Library, CNKI, and CBM was performed. Th...
Source: Cellular and Molecular Biology - January 27, 2024 Category: Molecular Biology Authors: Lijun Li Zhirui Zhao Xin Li Source Type: research
Cancers, Vol. 16, Pages 514: Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements
g Zhang
Myelofibrosis (MF) is an essential element of primary myelofibrosis, whereas secondary MF may develop in the advanced stages of other myeloid neoplasms, especially polycythemia vera and essential thrombocythemia. Over the last two decades, advances in molecular diagnostic techniques, particularly the integration of next-generation sequencing in clinical laboratories, have revolutionized the diagnosis, classification, and clinical decision making of myelofibrosis. Driver mutations involving JAK2, CALR, and MPL induce hyperactivity in the JAK-STAT signaling pathway, which plays a central role in cell survival and...
Source: Cancers - January 25, 2024 Category: Cancer & Oncology Authors: Tanvi Verma Nikolaos Papadantonakis Deniz Peker Barclift Linsheng Zhang Tags: Review Source Type: research
Reference intervals of cell population data parameters in Sysmex XN-Series and its patterns of changes from early adulthood to geriatric ages in South Korea
CONCLUSION: This study has determined comprehensive age- and sex-specific RIs for CPD parameters, which could help to prove the clinical significance of these parameters in the Sysmex XN-2000.PMID:38263481 | DOI:10.1111/ijlh.14231 (Source: International Journal of Laboratory Hematology)
Source: International Journal of Laboratory Hematology - January 24, 2024 Category: Hematology Authors: Yong Jun Choi Ju-Heon Park Seon Cho Hyeran Park Suyoung Kim Eunjoo Kwon Han-Ik Cho Eun-Hee Nah Source Type: research
Pretransplant hepatomegaly is linked to relapse in patients with leukemia and myelodysplastic syndrome not in remission
In conclusion, our findings suggest that the LI may be a risk factor for relapse in NonCR patients after allo-HCT.PMID:38252235 | DOI:10.1007/s12185-023-03707-7 (Source: International Journal of Hematology)
Source: International Journal of Hematology - January 22, 2024 Category: Hematology Authors: Yusuke Okayama Naonori Harada Yosuke Makuuchi Masatomo Kuno Teruhito Takakuwa Hiroshi Okamura Asao Hirose Mika Nakamae Mitsutaka Nishimoto Yasuhiro Nakashima Hideo Koh Masayuki Hino Hirohisa Nakamae Source Type: research
Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Bone Marrow Transplantation, Published online: 22 January 2024; doi:10.1038/s41409-023-02159-1Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - January 22, 2024 Category: Hematology Authors: Mar ía Queralt Salas Diderik-Jan Eikema Linda Koster Johan Maertens Jakob Passweg J ürgen Finke Annoek E. C. Broers Yener Koc Nicolaus Kr öger Zubeyde Nur Ozkurt Mar ía Jesús Pascual-Cascon Uwe Platzbecker Gwendolyn Van Gorkom Thomas Schroeder Jos é Source Type: research
Sequential gene expression analysis of myelodysplastic syndrome transformation identifies HOXB3 and HOXB7 as the novel targets for mesenchymal cells in disease
Myelodysplastic syndrome (MDS) is known to arise through the pathogenic bone marrow mesenchymal stem cells (MSC) by interacting with hematopoietic stem cells (HSC). However, due to the strong heterogeneity of ... (Source: BMC Cancer)
Source: BMC Cancer - January 22, 2024 Category: Cancer & Oncology Authors: Chunlai Yin, Yanqi Li, Cheng Zhang, Shizhu Zang, Zilong Wang, Xue Yan, Tonghui Ma, Xia Li and Weiping Li Tags: Research Source Type: research
